BODE Index
Predicts mortality in COPD using BMI, airflow obstruction, dyspnoea, and exercise capacity.
Score interpretation
BODE 0–2: Quartile 1. Low mortality. 4-year survival ~80%.
→ Optimise COPD management: smoking cessation, LABA/LAMA, pulmonary rehabilitation.
BODE 3–4: Quartile 2. Moderate mortality. 4-year survival ~67%.
→ Pulmonary rehabilitation. Consider specialist review. Optimise inhaler therapy.
BODE 5–6: Quartile 3. High mortality. 4-year survival ~57%.
→ Respiratory specialist review. Consider LVRS candidacy. Advanced care planning discussion.
BODE 7–10: Quartile 4. Very high mortality. 4-year survival ~18%.
→ Urgent specialist review. Lung transplantation evaluation. Palliative care planning.
Interpretation bands for the BODE. Apply clinical judgement and local guidance.
References
- Celli BR et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index. N Engl J Med. 2004.
Related
Curated clinical cross-links plus same-class fallbacks.
- Azithromycin (COPD Exacerbation Prophylaxis) · Macrolide antibiotic (anti-inflammatory / prophylactic)
- Doxycycline (COPD Exacerbation / CAP) · Oral tetracycline antibiotic
- Co-amoxiclav 625mg (COPD Exacerbation / CAP) · Beta-lactam / Beta-lactamase inhibitor combination antibiotic
- Fluticasone Furoate / Vilanterol · ICS/LABA — Asthma / COPD
- Beclometasone / Formoterol · ICS/LABA — Asthma / COPD
- Fluticasone Furoate / Umeclidinium / Vilanterol · Triple Therapy ICS/LAMA/LABA — COPD
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.